PDCD1 and non-small cell lung carcinoma: As programmed cell-death 1 (PD-1) and its ligand (PD-L1) targeted immunotherapy gradually becomes a predominant treatment modality, particularly for non-driver gene mutation patients, it significantly improves the survival rates of non-small cell lung cancer (NSCLC) patients.